| 纯度 | >90 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | CD70 |
| Uniprot No | P32970 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 39-193aa |
| 氨基酸序列 | QRFAQAQQQL PLESLGWDVA ELQLNHTGPQ QDPRLYWQGG PALGRSFLHG PELDKGQLRI HRDGIYMVHI QVTLAICSST TASRHHPTTL AVGICSPASR SISLLRLSFH QGCTIASQRL TPLARGDTLC TNLTGTLLPS RNTDETFFGV QWVRP |
| 预测分子量 | 20 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与CD70重组蛋白相关的文献示例(注：以下为模拟内容，实际文献需通过学术数据库查询)：
1. **文献名称**：CD70 as a therapeutic target in human malignancies
**作者**：Law CL et al.
**摘要**：探讨CD70在多种肿瘤细胞表面的异常表达，利用重组CD70蛋白验证其与受体CD27的相互作用，评估其作为免疫治疗靶点的潜力。
2. **文献名称**：Recombinant CD70 protein activates NK cells and enhances antitumor response
**作者**：Yang Z, Wang L
**摘要**：研究重组CD70蛋白对自然杀伤细胞(NK细胞)的激活作用，证明其通过CD27信号通路增强体外肿瘤细胞杀伤效果，提示其在联合治疗中的应用价值。
3. **文献名称**：Structural characterization of CD70-CD27 complex by recombinant protein analysis
**作者**：Zhang Y et al.
**摘要**：通过重组CD70蛋白与CD27的共结晶实验，解析两者结合的结构基础，为设计靶向抑制剂提供分子层面的依据。
*建议通过PubMed或Web of Science检索最新文献，使用关键词"CD70 recombinant protein"、"CD70 therapeutic"等获取更准确信息。*
**Background of CD70 Recombinant Protein**
CD70. a member of the tumor necrosis factor (TNF) superfamily, is a cell surface protein primarily expressed on activated immune cells (e.g., T cells, B cells, dendritic cells) and certain cancer cells. It interacts with its receptor CD27. a TNF receptor family member, to regulate immune responses, including T-cell activation, differentiation, and apoptosis. The CD70-CD27 axis plays dual roles in immunity: it promotes effector T-cell expansion and memory formation but can also suppress immune responses by inducing exhaustion or apoptosis under chronic stimulation.
Dysregulated CD70 expression is implicated in autoimmune diseases, viral infections, and cancers. Notably, CD70 is overexpressed in various malignancies, such as renal cell carcinoma, glioblastoma, and hematologic cancers, making it a potential therapeutic target. In cancer, CD70-CD27 interactions may foster tumor immune evasion by suppressing antitumor immunity or promoting pro-survival signaling in malignant cells.
Recombinant CD70 protein is engineered using genetic technology (e.g., mammalian or bacterial expression systems) to produce soluble, bioactive forms of the protein. This involves cloning the CD70 gene into expression vectors, followed by purification to ensure structural integrity and functional activity. Recombinant CD70 is widely used in research to study CD70-CD27 signaling mechanisms, screen therapeutic agents (e.g., blocking antibodies), and develop immunotherapies. For example, CD70-targeted therapies, including antibody-drug conjugates (ADCs) and CAR-T cells, are being explored in clinical trials.
Additionally, recombinant CD70 serves as a critical tool for in vitro and in vivo models to investigate immune modulation, tumor microenvironment interactions, and combination therapies. Its role in balancing immune activation and suppression highlights its therapeutic relevance in both oncology and autoimmune disease research.
In summary, CD70 recombinant protein bridges foundational immunology studies and translational applications, offering insights into disease mechanisms and paving the way for novel targeted therapies.
×
